RECENT DEVELOPMENTS IN HORMONAL TREATMENT
A. Advanced Disease
The most extensively investigated SERM other than tamoxifen in the setting of advanced breast cancer is toremifene. At least 5 randomized studies comparing toremifene 40 to 60 mg PO od with tamoxifen 20 to 40 mg PO od in postmenopausal, ER-positive or ER-unknown patients have been conducted, and a metanalysis of these trials has been published (Pyrhonen et al., 1999).
This looked at a cohort of 1421 patients, and all results were consistent with the criteria of statistical equivalence between toremifene and tamoxifen as first-line agents in metastatic disease. Toremifene has only limited activity as a second-line agent in patients who have relapsed Devamını Oku…